In 2023 alone, the US National Institutes of Health (NIH) poured $1.25 billion into research studying how mental illness ...
Bristol Myers Squibb's schizophrenia drug, which received FDA approval last week, took a long and winding road to get there. Three decades ago, Eli Lilly developed the drug's forerunner, xanomeline, ...
High MMP9 was associated with poor antipsychotic treatment response and changes in white matter density among patients with schizophrenia.
Such is the case with newly approved Bristol-Myers Squibb drug Cobenfy. The underlying drug was first studied in Alzheimer’s ...
Off the scrapheap of discarded drugs and on its way to becoming the most highly anticipated approval of 2024, Bristol Myers ...
For the first time in nearly 30 years, the U.S. Food and Drug Administration has approved a new drug treating schizophrenia, ...
Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...
Agents like semaglutide show promise for treatment of substance use disorders. Inaccessibility of GLP-1 agonists due to high ...
From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...
The California program is marking one year since it first rolled out in seven counties. It was billed as a way to get people ...
India Today on MSN9d
US FDA approves new schizophrenia drugThe US FDA has approved a new drug, Cobenfy, for treating schizophrenia in adults. This is a first new class for medication ...
The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback